This reference includes 77 antibody entries, 33 transfusion reactions and related complications, 27 blood-component and clinical-use entries, and 32 selected therapeutic apheresis entries, with clinical teaching notes, antibody/reaction chart-note templates, component clinical checklists, and therapeutic apheresis consult templates. It is a selected reference, not an exhaustive antigen catalog or a validated local transfusion policy.
Frequencies describe antigen-positive red cells, not antibody incidence or reaction probability. European / White, African / Black and Asian reflect broad historical source categories. They are not genetically uniform populations and cannot establish an individual's antigen status. Quantified population estimates appear where supported by the linked references. For other entries, the distribution summary explains prevalence, phenotype relationships, and donor availability. An omitted population estimate is not evidence that the antigen is absent. Rounded 100% estimates allow rare exceptions.
Most frequency data come from Dean's Blood Groups and Red Cell Antigens (2005). Clinical references include Canadian Blood Services (2025), NHSBT SPN214/5 (2022), LifeServe Blood Center, and additional publications linked in each entry. Source disagreements and clinical exceptions are retained. Lewis values represent predominant adult phenotypes.
IAT: indirect antiglobulin test at 37°C. HTR: hemolytic transfusion reaction. HDFN: hemolytic disease of the fetus and newborn. SCD: sickle cell disease. RhIG: Rh immune globulin. Confirm specificity, antibody history and local policy before clinical use. Replace every bracketed chart-note field before signing.
The upper-right badges classify antigen incidence and antibody significance separately. Red marks high-incidence antigens, clinically significant antibodies, or antibodies with documented potential significance. Green marks low-incidence antigens or usually insignificant antibodies. Amber identifies conditional significance or limited clinical evidence; neutral labels describe common/polymorphic or population-dependent antigens. Incidence terms follow cited transfusion references rather than a single numerical cutoff. A green incidence badge does not mean an antibody is harmless, and a green significance badge does not remove patient-specific exceptions.
Reaction entries include diagnosis, workup, management and selected facts with entry-specific sources. Surveillance case definitions are separate from clinical decisions. Rare or uncertain syndromes are labeled; no template makes a patient-specific diagnosis automatically.
The blood-component library includes component therapy, modifications, selected clinical-use strategies and entry-specific clinical checklists. Checklist marks are temporary, reset when an entry is opened, and are not stored as a patient record. AABB and the joint Circular provide the US reference base, supplemented by entry-specific supplier, FDA and international sources. Product-specific labeling and local policy govern handling; this website is not an extension of component labels.
The therapeutic apheresis library uses indication-specific ASFA 10th edition (September 2026) categories and grades, with original clinical summaries supported by separately linked clinical guidelines. Its selected entries do not reproduce the full ASFA fact-sheet collection. Consult templates contain prompts to complete in the patient chart; actual procedures require separate documentation.
To update the content, ask to edit this app. This version does not refresh medical sources automatically.